Clinical Trials

Galinpepimut-S shows a 41% reduction in risk of death in Phase 3 AML trial

SELLAS Life Sciences Group has reported positive topline results from its pivotal Phase 3 REGAL trial, in which its investigational WT1-targeted immunotherapeutic vaccine galinpepimut-S...
spot_imgspot_img